Search

Major changes needed for patients to benefit from precision medicine

Precision medicine approaches the treatment of a disease via an individual’s genes, environment, and lifestyle.

Read more

Pivotal Ruxolitinib Data Shows Promise for Patients with PV.

 

Polycythemia vera (PV) is a chronic, incurable blood cancer with limited treatment options. If uncontrolled, PV can cause serious cardiovascular complications, such as stroke and heart attack.

Read more

EHA-AHA-GBMA Mini Hematology Tutorial

For the first time EHA is collaborating simultaneously with the Armenian Hematology Association (AHA) and Georgian Association For Blood and Bone Marrow Transplantation (GBMTA) in a virtual Mini Hematology Tutorial.

Read more

How to apply

The CRTH 2025 call for applications is now closed. Timelines
Application CRTH 2025
Deadline: September 24, 2024 (15:00 CEST)

Notification
November 2024

Questions: training@ehaweb. orgDownload the Signature letter template.

Read more

Key messages of the 22nd Congress of EHA brought to the Middle East and North Africa

The second edition of the Highlights of Past EHA (HOPE) brought the key messages of the 22nd Congress of EHA to the Cairo, Egypt in September 2017.

Read more

EHA-Baltic Hematology Tutorial on Bleeding Disorders & Thrombosis

Dates: August 28-30, 2020 
Location: Riga, Latvia
Chairs: S Eichinger (EHA) & S Lejniece (LASH)

After a successful first edition, EHA is once again collaborating with the Latvian Society of Hematology (LASH), the Estonian Society of Hematology (EHS) and the Lithuanian Society of Hematology…

Read more

Support opportunities

View the EHA Ranking for 2025

EHA thrives on the support of the biomedical industry and the medical profession. The variety of opportunities available for industry range from educational activities to the EHA Congress.

Read more

Does the patient with myelofibrosis feel better through Pacritinib?

Pacritinib is an oral next-generation multikinase inhibitor with specificity for JAK2 and FLT3 being evaluated to treat myelofibrosis in two Phase 3 trials.

Read more